Transferability of health cost evaluation across locations in oncology: cluster and principal component analysis as an explorative tool

Perrier, Lionel; Buja, Alessandra; Mastrangelo, Giuseppe; Baron, Patrick Sylvestre; Ducimetière, Françoise; Pauwels, Petrus J.; Róssi, Carlo; Gilly, François Noël; Martin, Amaury; Favier, Bertrand; Farsi, Fadila; Laramas, Mathieu; Baldo, Vincenzo; Collard, Olivier; Cellier, Dominique; Blay, Jean‐Yves; Ray‐Coquard, Isabelle

doi:10.1186/s12913-014-0537-x

Cited by 10 publications

(8 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further research activities could be designed, adopting a whole-disease model based on EU-shared clinical pathways, and including costs by country for each procedure or treatment in the model in order to enable an estimation of the local average costs of melanoma patients by disease stage. In fact, it has been demonstrated that there is still some discrepancy between the costs of cancer patient management in different countries, despite a consensus on the related clinical practice guidelines (43).…”

Section: Discussionmentioning

confidence: 99%

Estimation of Direct Melanoma-related Costs by Disease Stage and by Phase of Diagnosis and Treatment According to Clinical Guidelines

Buja¹,

Sartor²,

Scioni³

et al. 2018

Acta Derm Venerol

View full text Add to dashboard Cite

Cutaneous melanoma is a major concern in terms of healthcare systems and economics. The aim of this study was to estimate the direct costs of melanoma by disease stage, phase of diagnosis, and treatment according to the pre-set clinical guidelines drafted by the AIOM (Italian Medical Oncological Association). Based on the AIOM guidelines for malignant cutaneous melanoma, a highly detailed decision-making model was developed describing the patient's pathway from diagnosis through the subsequent phases of disease staging, surgical and medical treatment, and follow-up. The model associates each phase potentially involving medical procedures with a likelihood measure and a cost, thus enabling an estimation of the expected costs by disease stage and clinical phase of melanoma diagnosis and treatment according to the clinical guidelines. The mean per-patient cost of the whole melanoma pathway (including one year of follow-up) ranged from €149 for stage 0 disease to €66,950 for stage IV disease. The costs relating to each phase of the disease's diagnosis and treatment depended on disease stage. It is essential to calculate the direct costs of managing malignant cutaneous melanoma according to clinical guidelines in order to estimate the economic burden of this disease and to enable policy-makers to allocate appropriate resources.

show abstract

Section: Discussionmentioning

confidence: 99%

Estimation of Direct Melanoma-related Costs by Disease Stage and by Phase of Diagnosis and Treatment According to Clinical Guidelines

Buja¹,

Sartor²,

Scioni³

et al. 2018

Acta Derm Venerol

View full text Add to dashboard Cite

show abstract

“…In most cases, such policy-level decisions are highly specific to location, country, and system, and meta-analytic approaches are often inappropriate. [40][41][42] Given these practical barriers and theoretical contraindications for a quantitative analysis, qualitative synthesis was employed to aggregate results of individual studies included in this systematic review.…”

Section: Synthesis Of Resultsmentioning

confidence: 99%

The Impact of Treatments for OSA on Monetized Health Economic Outcomes

Wickwire

Albrecht

Towe

et al. 2019

Chest

View full text Add to dashboard Cite

To review systematically the published literature regarding the impact of treatment for OSA on monetized health economic outcomes. METHODS: Customized structured searches were performed in PubMed, Embase (Embase. com), and the Cochrane Central Register of Controlled Trials (Wiley) databases. Reference lists of eligible studies were also analyzed. Titles and abstracts were examined, and articles were identified for full-text review. Studies that met inclusion criteria were evaluated in detail, and study characteristics were extracted using a standardized template. Quantitative characteristics of the studies were summarized, and a qualitative synthesis was performed. RESULTS: Literature searches identified 2,017 nonredundant abstracts, and 196 full-text articles were selected for review. Seventeen studies met inclusion criteria and were included in the final synthesis. Seven studies included formal cost-effectiveness or cost-utility analyses. Ten studies employed cohort designs, and four studies employed randomized controlled trial or quasi-experimental designs. Positive airway pressure was the most common treatment modality, but oral appliances and surgical approaches were also included. The most common health economic outcomes were health-care use (HCU) and quality-adjusted life years (QALYs). Follow-ups ranged from 6 weeks to 5 years. Overall, 15 of 18 comparisons found that treatment of OSA resulted in a positive economic impact. Treatment adherence and OSA severity were positively associated with cost-effectiveness. CONCLUSIONS: Although study methodologies varied widely, evidence consistently suggested that treatment of OSA was associated with favorable economic outcomes, including QALYs, within accepted ranges of cost-effectiveness, reduced HCU, and reduced monetized costs.

show abstract

“…Although many factors influencing transferability have been identified [ 16 , 17 , 22 ], when imputing missing costs in a data-scarce setting, adjustments may only be feasible based on a limited number of available parameters. Motivated by the rapid de facto HTA assessments applied for Eastern Europe and other resource-limited settings [ 18 , 30 , 31 ], we assumed that missing costs can be imputed after adjusting only for a single macroeconomic indicator, such as gross domestic product per capita (GDPpc), total health expenditure per capita (THEpc) or governmental health expenditure per capita (GHEpc).…”

Section: Methodsmentioning

confidence: 99%

Disease-Related Costs Published in The Middle East and North Africa Region: Systematic Review and Analysis of Transferability

et al. 2022

View full text Add to dashboard Cite

Background In the Middle East and North Africa (MENA) the scarcity of local cost data is a key barrier to conducting health economic evaluations. We systematically reviewed reports of disease-related costs from MENA and analysed their transferability within the region. Methods We searched PubMed and included full text English papers that reported disease-related costs from the local populations of Algeria, Bahrain, Egypt, Iraq, Jordan, Saudi Arabia, Kuwait, Lebanon, Libya, Morocco, Oman, Palestine, Qatar, Syria, Tunisia, United Arab Emirates and Yemen between 1995 and 2019. Screening, study selection and data extraction were done in duplicate. Study-related variables, costing methods, all costs and their characteristics were extracted and analysed via descriptive methods. From multi-country studies of MENA employing homogenous costing methods, we estimated the ratio (cost transfer coefficient) between the relative differences in direct medical costs and macroeconomic indicators via robust regression. We predicted each cost via the estimated cost transfer formula and evaluated prediction error between true and predicted (transferred) costs. Results The search yielded 1646 records, 206 full text papers and 3525 costs from 84 diagnoses. Transferability was analysed involving 144 direct medical costs from eight multi-country studies. Adjusting the average of available foreign costs by 0.28 times the relative difference in GDP per capita provided the most accurate estimates. The correlation between true and predicted costs was 0.96; 68% of predicted costs fell in the true ± 50% range. Predictions were more accurate for costs from studies that involved the largest number of countries, for countries outside the Gulf region and for drug costs versus unit or disease costs. Conclusion The estimated cost transfer formula allows the prediction of missing costs in MENA if only GDP per capita is available for adjustment to the local setting. Input costs for the formula should be collected from multiple sources and match the decision situation. Supplementary Information The online version contains supplementary material available at 10.1007/s40273-022-01146-6.

show abstract

Transferability of health cost evaluation across locations in oncology: cluster and principal component analysis as an explorative tool

Cited by 10 publications

References 36 publications

Estimation of Direct Melanoma-related Costs by Disease Stage and by Phase of Diagnosis and Treatment According to Clinical Guidelines

Estimation of Direct Melanoma-related Costs by Disease Stage and by Phase of Diagnosis and Treatment According to Clinical Guidelines

The Impact of Treatments for OSA on Monetized Health Economic Outcomes

Disease-Related Costs Published in The Middle East and North Africa Region: Systematic Review and Analysis of Transferability

Contact Info

Product

Resources

About